Omega-3 EPA/DHA (Eicosapentaenoic Acid / Docosahexaenoic Acid)
SupplementThe medical score substantially exceeds the community score because the clinical evidence (38 RCTs, n=149,051) [s2] primarily demonstrates improvements in cardiovascular and metabolic laboratory parameters that are barely perceptible to users subjectively. Community perception is dominated by the view that short-term effects are absent or difficult to attribute [c1, c2].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Omega-3 (EPA/DHA) is among the best-evidenced supplements available: a meta-analysis of 38 RCTs with over 149,000 patients confirms cardiovascular benefits, and triglyceride reduction at 2–4 g/day is dose-dependent and robustly reproducible. EPA-dominant formulas show consistent, moderate antidepressant effects. The safety profile is excellent up to 5 g/day, but product quality is a genuine concern — many fish oil capsules on the market are oxidized and therefore ineffective or counterproductive. IFOS certification or algae oil are the practical solutions.
Description
Marine omega-3 fatty acids (EPA and DHA) from fish oil or algal oil with demonstrated effects on triglycerides, inflammatory markers, and cardiovascular endpoints [s2, s3, s4].
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are long-chain polyunsaturated omega-3 fatty acids (LC-PUFA) that the human body can synthesize only to a very limited extent from the plant precursor ALA (alpha-linolenic acid) [s5]. Primary sources are fatty marine fish, krill, and marine microalgae. Bioavailability varies by formulation: triglyceride forms (TG) and re-esterified triglycerides (rTG) show higher absorption than ethyl esters (EE), as EE require an additional enzymatic step [s6, s7]. Acute absorption differences may, however, equalize with chronic supplementation [s5]. The best-documented clinical effect is the reduction of elevated triglyceride levels, which is linearly dose-dependent at doses of 2–4 g EPA+DHA/day [s3, s4]. Several large meta-analyses encompassing over 149,000 patients have examined cardiovascular endpoints; effects on major MACE events are moderate and inconsistent at standard doses, whereas high-dose EPA monotherapy (REDUCE-IT trial with icosapent ethyl) demonstrated a significant reduction in MACE [s2, s8]. For depression, meta-analyses show a moderate effect of EPA-predominant formulations (EPA fraction >50% of total dose) [s9]. EFSA confirms health claims for: normal cardiac function (250 mg EPA+DHA/day), brain function and vision (250 mg DHA/day), triglyceride reduction (2–4 g/day), and blood pressure regulation [s12]. The safety upper limit according to EFSA is 5 g EPA+DHA/day [s1].
Legal Status (DE)
EPA and DHA are freely marketable as over-the-counter dietary supplements (DS) in the DACH countries [s1, s12]. High-dose pure preparations (e.g., icosapent ethyl/Vascepa) are prescription-only (Rx) in the United States but are not approved as medicinal products in Germany or the EU [s13]. EFSA-authorized health claims for EPA+DHA exist under Regulation (EU) No. 432/2012 (heart, brain, eyes, triglycerides, blood pressure) [s12]. The BfR recommends maximum amounts for dietary supplements and advises medical consultation for individuals with cardiovascular disease [s1].
Mechanism of Action
EPA and DHA are incorporated into cell membranes, where they influence membrane fluidity and the function of receptors and ion channels [s5]. Their primary mechanisms of action: 1. Eicosanoid modulation: EPA displaces arachidonic acid (AA) as a substrate for COX and LOX enzymes. EPA-derived eicosanoids (series-3 prostaglandins, series-5 leukotrienes) have lower pro-inflammatory potency than AA-derived counterparts [s10, s11]. 2. Specialized pro-resolving mediators (SPM): EPA and DHA are precursors of resolvins (E-series from EPA, D-series from DHA), protectins, and maresins. These SPMs actively promote resolution of inflammation via inhibition of neutrophil recruitment, macrophage polarization toward the M2 phenotype, and stimulation of apoptotic cell clearance [s10, s11]. 3. Triglyceride reduction: EPA+DHA reduce hepatic VLDL production (inhibition of diacylglycerol acyltransferase, DGAT), enhance mitochondrial β-oxidation, and increase lipoprotein lipase activity [s3]. 4. Antithrombotic: EPA and DHA inhibit thromboxane A2 synthesis from AA, thereby reducing platelet aggregation [s1]. 5. Neuronal function: DHA constitutes approximately 10–15% of fatty acids in the cerebral cortex and is required for normal neuronal membrane fluidity, neurotransmitter receptor function, and synaptic plasticity [s14].
Dosing
Allgemeine kardiovaskuläre Gesundheit / Herzfunktion (EFSA Health Claim)
- Dose
- 250–500 mg EPA+DHA combined
- Frequency
- 1× täglich
- Route
- oral
- Duration
- fortlaufend
- Timing
- With a fatty meal (improves absorption of ethyl ester forms)
- With food
- empfohlen
Triglycerid-Senkung
- Dose
- 2,000–4,000 mg EPA+DHA combined
- Frequency
- aufgeteilt auf 2 Dosen
- Route
- oral
- Duration
- ≥8 Wochen, dann Kontrolle
- Timing
- With meals
- With food
- empfohlen
Unterstützung bei Depression (EPA-betonte Formel)
- Dose
- 1,000–2,000 mg EPA (EPA fraction >50% of total dose)
- Frequency
- 1–2× täglich
- Route
- oral
- Duration
- ≥8 Wochen
- Timing
- With a meal
- With food
- empfohlen
Schwangerschaft (fetale Entwicklung, Gehirn/Augen)
- Dose
- 450 mg DHA+EPA daily (min. 200 mg DHA)
- Frequency
- 1× täglich
- Route
- oral
- Duration
- Gesamte Schwangerschaft und Stillzeit
- Timing
- With a meal
- With food
- empfohlen
EFSA considers up to 5 g EPA+DHA/day safe for the general population [s1]. The BfR recommends maximum amounts for dietary supplements and advises medical consultation for individuals with cardiovascular disease [s1]. A maximum of 3 g/day is recommended for pregnant women [s15].
Ethyl ester preparations should always be taken with a fat-containing meal, as absorption is markedly reduced in the fasted state [s5, s6]. Triglyceride and rTG forms are less meal-dependent [s6, s7]. Attention should be paid to oxidative freshness (peroxide value, manufacturing date) [c1].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Fischartiger Nachgeschmack, Aufstoßen (Fishy Burps) Most common side effect with capsule formulations, particularly ethyl ester forms. Enteric coating or administration with meals reduces the problem [s16]. | häufig | leicht |
| Gastrointestinale Beschwerden (Übelkeit, Sodbrennen, Durchfall) More frequently reported at doses >3 g/day; generally reducible by splitting the daily dose into multiple administrations [s1, s16]. | gelegentlich | leicht |
| Erhöhte Blutungsneigung / verlängerte Blutungszeit At doses of 2–15 g/day via inhibition of platelet aggregation. Clinically relevant bleeding events rare at ≤5 g/day according to EFSA [s1]. | gelegentlich | moderat |
| Vorhofflimmern (Atrial Fibrillation) Increased AF risk observed with high-dose omega-3 supplements (≥4 g/day) in multiple RCTs and meta-analyses, particularly in individuals with pre-existing cardiac disease [s2, s8]. | gelegentlich | moderat |
| LDL-Cholesterin-Erhöhung Occasional mild LDL increases reported mainly with ethyl ester preparations and high doses; DHA-predominant preparations more frequently associated than EPA-mono [s3, s4]. | gelegentlich | leicht |
| Allergische Reaktionen bei Fischallergie Fish oil-based products may trigger reactions in individuals with existing fish allergy; algal oil recommended as an alternative [s1]. | selten | schwer |
Contraindications
Fish oil and krill oil supplements may contain allergenic fish proteins. Algae oil is suitable for this group [s1].
Omega-3 fatty acids inhibit platelet aggregation and may potentiate the anticoagulant effect of anticoagulants. Increased bleeding risk at higher doses (>3 g/day) [s17, s18].
EPA+DHA are hepatically metabolized; safety in severe hepatic impairment is insufficiently established [s1].
Meta-analyses show increased risk of atrial fibrillation with high-dose omega-3 supplements; risk-benefit assessment required [s2, s8].
Interactions
Synergistic
Omega-3 and CoQ10 complement each other cardiovascularly and mitochondrially. Omega-3 lowers triglycerides and inhibits lipid peroxidation; CoQ10 acts as an antioxidant and supports cellular energy. Animal studies demonstrate synergistic antiatherosclerotic effects.
Astaxanthin, as a lipid-soluble carotenoid, protects the polyunsaturated fatty acids EPA and DHA from lipid peroxidation. The combination is found in commercial products (e.g., krill oil) and supports cardiovascular health.
Omega-3 fatty acids, as a lipophilic carrier matrix, enhance absorption of fat-soluble vitamin D3. Both nutrients exhibit synergistic and overlapping mechanisms in inflammation, cardiovascular, and metabolic health.
Studies
Tier A — High Evidence
Outcome: Depression severity (standardized rating scales)
Effect Size: Significant reduction in depression symptoms; EPA-predominant formulations (EPA >50%) more effective than DHA-predominant
Outcome: Triglyceride reduction, plaque volume in coronary artery disease
Effect Size: Near-linear relationship between EPA+DHA dose and triglyceride reduction; significant reduction at 2–4 g/day
Outcome: Triglyceride reduction, LDL cholesterol, HDL cholesterol
Effect Size: Near-linear association between omega-3 intake and triglyceride reduction; no significant LDL effect
Outcome: Cardiovascular mortality, non-fatal myocardial infarction, stroke (MACE)
Effect Size: EPA+DHA: relative risk reduction for cardiovascular mortality; significant triglyceride lowering; increased AF risk with high-dose formulations
Tier B — Moderate Evidence
Outcome: MACE, myocardial infarction, stroke
Effect Size: No significant effect on MACE at standard doses; results heterogeneous depending on formulation used (EE vs. TG)
Outcome: Mechanisms of anti-inflammatory action of EPA and DHA
Effect Size: Mechanistically established: reduction of TNF, IL-1β, IL-6; induction of resolvins and protectins
Tier C — Low Evidence
Outcome: Bioavailability of EPA+DHA in various chemical forms (TG, EE, MAG)
Effect Size: FFA > TG > EE; ethyl esters have lowest bioavailability in acute dosing
Community Evidence
Top reported benefits
- Reduction of joint pain and sensation of inflammation
- Improved mood and emotional stability
- Improved skin appearance (less acne, reduced oiliness)
- Better blood lipid levels per medical monitoring
- Increased VO2max and athletic recovery
Top reported issues
- No immediate perceptible effect; effects only apparent after weeks
- Fishy aftertaste and belching (fish burps)
- Quality concerns: many products possibly oxidized/rancid
- High cost for adequately dosed quality preparations
- Difficult dose calculation: EPA+DHA content varies considerably between products
The community frequently highlights inadequate quality control of many fish oil products (rancidity, insufficient EPA+DHA content per capsule) [c1, c2]. Users recommend IFOS-certified products or switching to algal oil as a more oxidation-stable alternative [c2, c3]. Several users report that fish as a dietary source is more cost-effective and efficacious than capsules [c2].
Scientific Sources
- Omega-3 Fatty Acids – Health Professional Fact Sheet
National Institutes of Health (NIH), Office of Dietary Supplements (2024). NIH Office of Dietary SupplementsBLink - Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?
Calder PC (2013). British Journal of Clinical Pharmacology (PMC)BPMID:22765297 - Omega-3 Fatty Acids and Inflammatory Processes
Calder PC (2012). Nutrients (PMC)BPMID:22254094 - Regulatory Compliance of Health Claims on Omega-3 Fatty Acid Food Supplements
Biesalski HK, et al. (2025). PMC / NutrientsALink - FDA approves omega-3 fish-oil medication Vascepa to reduce risk of death in people with high cholesterol
ABC News / Amarin Press Release (2019). ABC News / FDABLink - Omega-3 Fatty Acids – StatPearls
Swanson D, Block R, Mousa SA (2024). StatPearls / NCBI BookshelfBLink - Fischöl für Schwangere: Nicht zu hoch dosieren
aponet.de Redaktion (2023). aponet.deCLink - Omega-3 Fatty Acids – Sicherheitsbewertung
DocMedicus Vitalstofflexikon Redaktion (2023). vitalstoff-lexikon.deCLink - Omega-3 Supplementation and Potential Drug Interactions with Eliquis
Accurate Clinic Editorial (2023). accurateclinic.comCLink - Vorsicht bei Omega-3 und Cumarinen
APOTHEKE ADHOC Redaktion (2022). apotheke-adhoc.deCLink - N-3 Fatty Acids (EPA and DHA) and Cardiovascular Health – Updated Review of Mechanisms and Clinical Outcomes
Skulas-Ray AC, et al. (2025). PMC / Nutrients (review)ALink - Effects of Omega-3 Fatty Acids Intake on Lipid Metabolism and Plaque Volume in Patients With Coronary Heart Disease: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials
Zhang Y, et al. (2025). Food Science & NutritionADOI - Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials
Bernasconi AA, Wiest MM, Lavie CJ, et al. (2024). Journal of the American Heart AssociationADOI - Bioavailability of EPA and DHA in humans – A comprehensive review
Schuchardt JP, Hahn A (2024). Prostaglandins, Leukotrienes and Essential Fatty AcidsBDOI - Comparison of pharmacokinetics of omega-3 fatty acid supplements in monoacylglycerol or ethyl ester in humans: a randomized controlled trial
Dyerberg J, Bang HO, Stoffersen E, et al. (2020). European Journal of Clinical NutritionADOI - Omega-3 forms explained: Ethyl Esters vs. Triglycerides and their bioavailability differences
Nordic Fish Oil (nfo.com) (2023). nfo.com (industry review)CLink - Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis
Abdelhamid AS, Brown TJ, Brainard JS, et al. (2021). PMC / EClinicalMedicineALink - Efficacy and safety of n-3 fatty acids supplementation on depression: a systematic review and dose-response meta-analysis of randomised controlled trials
Liao Y, Xie B, Zhang H, et al. (2024). British Journal of NutritionALink
Community Sources
Storage
Unopened
Store cool (8–15 °C) and dark, protected from oxygen and direct light. Store liquid oils in the refrigerator.
Opened
Consume promptly after opening (liquid oils within 3 months). Store capsules in a cool, dry place with the container tightly closed.
Notes
Omega-3 fatty acids are susceptible to oxidative rancidity. Spoiled products have a strong fishy-rancid odor and should no longer be consumed. Antioxidants (vitamin E/tocopherols) in the formulation slow oxidation. Quality products carry TOTOX or IFOS certification [c1].